Press Release : Roche's Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Message : Required fields -- Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study -- Tecentriq approval offers an alternative to chemotherapy for all eligible patients -- This approval marks Tecentriq's fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EU Basel, 5 May 2021 -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq(R) (atezolizumab) as a first-line (ini...
Source: marketscreener.com
